1421693-22-2 Usage
Description
CDKI-73, also known as 3-[[5-Fluoro-4-[4-methyl-2-(methylamino)-5-thiazolyl]-2-pyrimidinyl]amino]benzenesulfonamide, is a potent cyclin-dependent kinase (CDK) inhibitor derived from a class of compounds that play a crucial role in regulating cell cycle progression. It specifically targets CDK9, a protein involved in various cellular processes, including transcription and cell cycle regulation. CDKI-73 has demonstrated significant efficacy against acute myeloid leukemia, making it a promising candidate for further research and development in the field of oncology.
Uses
Used in Oncology:
CDKI-73 is used as a CDK9 inhibitor for the treatment of acute myeloid leukemia (AML). It has shown to be highly efficacious in targeting CDK9, which plays a critical role in the development and progression of AML. By inhibiting CDK9, CDKI-73 can potentially disrupt the abnormal cell cycle and proliferation of leukemia cells, leading to the suppression of tumor growth and improved patient outcomes.
Used in Drug Development:
In the pharmaceutical industry, CDKI-73 is used as a lead compound for the development of novel CDK inhibitors. Its potent activity against CDK9 makes it a valuable starting point for designing and synthesizing new drugs that can target various types of cancer, including solid tumors and hematological malignancies. The development of CDK inhibitors like CDKI-73 can lead to the creation of more effective and targeted cancer therapies with fewer side effects compared to conventional chemotherapy.
Used in Research:
CDKI-73 is also used as a research tool in the field of cell biology and oncology. It can be employed to study the role of CDK9 in various cellular processes, such as transcription, cell cycle regulation, and apoptosis. By understanding the molecular mechanisms underlying the action of CDKI-73, researchers can gain valuable insights into the development of cancer and the potential therapeutic strategies for its treatment.
Check Digit Verification of cas no
The CAS Registry Mumber 1421693-22-2 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,4,2,1,6,9 and 3 respectively; the second part has 2 digits, 2 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 1421693-22:
(9*1)+(8*4)+(7*2)+(6*1)+(5*6)+(4*9)+(3*3)+(2*2)+(1*2)=142
142 % 10 = 2
So 1421693-22-2 is a valid CAS Registry Number.
1421693-22-2Relevant articles and documents
A method for preparing such CDK inhibitors (by machine translation)
-
, (2017/10/05)
The invention discloses a method for preparing such CDK inhibitors, will be single-methyl thiourea and 1 - N monochloride reaction, 4 - dimethylthiazole - 2 - amine, by bromo reaction to obtain 5 - bromo - N, 4 - dimethylthiazole - 2 - amine, under the action of the catalyst after the with the borate to obtain aromatic borate intermediates; aromatic borate ester intermediate with 2, 4 - dichloro - 5 fluoro uracil in the noble metal catalytic under suzuki coupling reaction to obtain the coupling product to continue after the Buchwald - Hartwig with the aromatic amine in the reaction, ultimately to obtain the target product. (by machine translation)
THERAPEUTIC COMPOUNDS
-
Paragraph 00168, (2013/11/05)
The present invention relates to compounds of formula (I): wherein R1 is NH2 or NHMe; R2 is halo; and one of R3 or R4 is hydrogen and the other is selected from –SO2NH2, -SO2NHMe or –SO2NMe2, -SO2NHEt, or -SO2NEt2; or a pharmaceutically acceptable salt or solvate thereof. The compounds of formula (I) are inhibitors of protein kinases, especially cyclic dependent kinases (CDKs) such as CDK9. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which protein kinase/CDK activity is implicated.
